Literature DB >> 31302454

Predictors of autoimmune hemolytic anemia in beta-thalassemia patients with underlying red blood cells autoantibodies.

Monia Ben Khaled1, Monia Ouederni2, Nessrine Sahli2, Nawel Dhouib3, Ahmed Ben Abdelaziz4, Samia Rekaya2, Ridha Kouki2, Houda Kaabi5, Hmida Slama5, Fethi Mellouli2, Mohamed Bejaoui2.   

Abstract

In beta-thalassemia patients, erythrocyte autoantibodies can remain silent or lead to Autoimmune Hemolytic Anemia (AIHA).The aim of this study was to identify predictors of AIHA in beta-thalassemia patients with positive Direct Antiglobulin Test (DAT), in Tunisia. This longitudinal prognosis study was carried out on beta-thalassemia patients with a positive confirmed DAT. Predictors of AIHA were identified the Kaplan-Meier method. A Cox model analysis was used to identify independent predictors. Among 385 beta thalassemia patients, 87 developed positive DAT (22.6%). Autoimmune hemolytic anemia was occurred in 25 patients. Multivariate analysis showed that AIHA was independently associated with beta-thalassemia intermedia and similar family history of AIHA. Splenectomy in patients with positive DAT was independently associated with an increased risk of AIHA (HR = 6.175, CI: 2.049-18.612, p < 0.001). The risk of developing AIHA was higher during the first 72 transfusions. Autoimmune hemolytic anemia was significantly associated with polyspecific DAT (anti-complement and anti-IgG), blood group AB and prior alloimmunization. Whereas transfusion by phenotypic and leukoreduced blood was a protective factor. In summary, splenectomy after autoimmunization, prior alloimmunization, DAT specificity (IgG with complement), thalassemia intermedia, AB blood group and family history of AIHA were strongly associated with AIHA. Leukoreduced blood transfusion had a proven preventive role.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoantibodies; Autoimmune hemolytic anemia; Direct antiglobulin test; Red blood cells; Thalassemia; Transfusion

Year:  2019        PMID: 31302454     DOI: 10.1016/j.bcmd.2019.102342

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  3 in total

1.  Red blood cell alloimmunization and other transfusion-related complications in patients with transfusion-dependent thalassemia: A multi-center study in Thailand.

Authors:  Nattiya Teawtrakul; Duantida Songdej; Chattree Hantaweepant; Adisak Tantiworawit; Supanun Lauhasurayotin; Kitti Torcharus; Pornpun Sripornsawan; Pranee Sutcharitchan; Pacharapan Surapolchai; Patcharee Komvilaisak; Supawee Saengboon; Bunchoo Pongtanakul; Pimlak Charoenkwan
Journal:  Transfusion       Date:  2022-08-20       Impact factor: 3.337

2.  Comprehensive management of refractory autoimmune hemolytic anemia in pediatric beta-thalassemia major patient: A case report.

Authors:  Vincencius William; Desy Rusmawatiningtyas; Firdian Makrufardi; Pudjo Hagung Widjajanto
Journal:  Ann Med Surg (Lond)       Date:  2021-09-13

3.  Direct antiglobulin test-negative autoimmune hemolytic anemia in a patient with β-thalassemia minor during pregnancy: A case report.

Authors:  Yang Zhou; Yi-Ling Ding; Li-Juan Zhang; Mei Peng; Jian Huang
Journal:  World J Clin Cases       Date:  2022-02-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.